Guillain-Barré syndrome as an atypical manifestation of an esophageal carcinoma

Zilli, Thomas; Allal, Adbelkarim S.

doi:10.1007/s10072-010-0363-9

Cited by 9 publications

(8 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4 However, whether GBS is a marker of occult cancer remains unclear. Available evidence is limited to case reports [5][6][7][8][9][10][11][12][13][14][15][16][17][18] and two small regional, single-hospital cohort studies, which included 435 and 109 GBS patients, respectively. 19,20 In both cohorts, a two-fold increased incidence of cancer was reported among GBS patients compared with the cancer incidence expected in the general population, based on nine and 10 cancer cases, respectively.…”

Section: Introductionmentioning

confidence: 99%

Cancer Diagnosis and Prognosis After Guillain–Barré Syndrome: A Population-Based Cohort Study

Girma

Farkas²,

Laugesen³

et al. 2022

CLEP

View full text Add to dashboard Cite

Introduction It is unclear whether Guillain–Barré syndrome (GBS) can be a marker of a paraneoplastic syndrome. We examined whether GBS is associated with cancer and whether the prognosis of GBS patients with cancer differs from that of other cancer patients. Materials and Methods We conducted a population-based cohort study of patients diagnosed with GBS between 1978 and 2017 using Danish registry-data. Main outcome measures were cancer incidence and mortality after cancer diagnosis. We calculated absolute risks of a cancer diagnosis, treating death as competing risk, and standardized incidence ratios (SIRs) as measures of relative risk. We matched each GBS cancer patient with up to 10 cancer patients without a GBS diagnosis and examined the six-month survival after cancer diagnosis using Cox regression analysis. Results We identified 7897 patients (58% male, median age 57 years) with GBS. During a median follow-up of 9.5 years, the one-year risk of cancer was 2.7% (95% confidence interval (CI), 2.4–3.1). The SIR was increased throughout follow-up, but most noticeably during the first year after diagnosis (SIR: 3.35, 2.92–3.83). SIRs were particularly elevated for hematologic cancers (SIR: 8.67, 6.49–11.34), smoking-related cancers (SIR: 3.57, 2.81–4.47), and cancers of neurological origin (SIR: 8.60, 5.01–13.77). Lung cancer was the main contributor to the overall excess risk, which persisted after 36 months of follow-up (SIR: 1.17, 1.09–1.25). The mortality rate ratio comparing patients diagnosed with any cancer within one year of their GBS diagnosis and matched GBS-free cancer cohort members was 1.56 (95% CI, 1.27–1.90). Conclusion GBS patients had a three-fold increased risk of cancer diagnosis in the first year of follow-up. The absolute cancer risk was almost 3.0%. A GBS diagnosis was an adverse prognostic marker for survival following cancer diagnosis. Clinicians should consider occult cancer in patients hospitalized with GBS.

show abstract

Section: Introductionmentioning

confidence: 99%

Cancer Diagnosis and Prognosis After Guillain–Barré Syndrome: A Population-Based Cohort Study

Girma

Farkas²,

Laugesen³

et al. 2022

CLEP

View full text Add to dashboard Cite

show abstract

“…The presence of paraneoplastic GBS remains controversial but there are reports of GBS occurring in the presence of different types of cancers including lung cancer [ 3 - 10 ], non-lung squamous cell carcinoma [ 11 ], gastrointestinal cancers [ 12 , 13 ], bladder cancer [ 14 ], and lymphomas [ 15 , 16 ]. Here, we report a case of a 61-year-old man with untreated squamous cell carcinoma of the lung diagnosed with rapidly progressing GBS.…”

Section: Introductionmentioning

confidence: 99%

A Case of Paraneoplastic Guillain-Barré Syndrome Associated with Squamous Cell Carcinoma of the Lung

Liu

Baldinger

et al. 2018

Cureus

View full text Add to dashboard Cite

We report a case of a 61-year-old man with a history of squamous cell carcinoma of the lung presenting with rapidly progressive symmetric ascending weakness with areflexia. The weakness was quickly followed by respiratory decompensation requiring intubation. Lumbar puncture yielded cerebrospinal fluid with elevated protein (177 mg/dL), normal glucose (61 mg/dL), normal red blood cell count (0 per/µl), and normal white blood cell count (0 per/µL). Emergent magnetic resonance imaging of cervical, thoracic, and lumbar spine did not show evidence of metastatic disease, fracture, subluxation, or other causes of cord compression. The patient was diagnosed with acute inflammatory polyneuropathy, also known as Guillain-Barré syndrome. Despite treatment with a five-day course of intravenous immunoglobulin and a subsequent five-day course of plasmapheresis, the patient did not recover respiratory function and died 48 days after diagnosis. To our knowledge, this is the first documented case of Guillain-Barré occurring concomitantly with squamous cell carcinoma of the lung.

show abstract

“…GBS has also been linked to malignancies as a possible paraneoplastic complication. Tumours associated with GBS are lymphomas, breast, small-cell lung, renal and oesophageal carcinomas [8].…”

Section: Introductionmentioning

confidence: 99%

Paraneoplastic syndromes in daily clinical practice

Wójtowicz¹,

Rękas-Wójcik²,

Lipa³

et al. 2015

J Pre Clin Clin Res.

View full text Add to dashboard Cite

Paraneoplastic syndromes consist of disorders that accompany benign and malignant tumours, but are not directly related to mass effects or invasion by the primary tumour or its metastases. The pathophysiology of mostly paraneoplastic syndromes is not well known. The usual mechanism of their development is the aberrant production of substances (protein hormones, hormone precursors or hormone-like substances) by tumour tissue or autoimmune disorder. The neurological paraneoplastic syndromes are autoimmune disorders that can affect almost any part of the nervous system. The endocrine paraneoplastic syndromes are often certain clinical syndromes like paraneoplastic hypercalcaemia or the aberrant production of hormones by cancers. Many haematologic conditions, including anaemia, leucocytosis, thrombocytopenia or thrombocytosis, coagulapathy have been reported in association with cancer. Also paraneoplastic rheumatic syndromes have been reported in association of cancer. Skin can be involved in cancer in different ways: by metastases, as a part of a genetic disorder with a cutaneous component in which there is an inherited predisposition to the later development of malignancy, as a part of an acquired syndrome due to the toxicity of a carcinogen that induces malignant change and accompanying skin changes, as a consequence of immunosuppression, or by the development of specific lesions that occur as a paraneoplastic syndromes The most frequently diagnosed dermatologic conditions include acrokeratosis paraneoplastica, Sweet's syndrome and paraneoplastic pemphigus. The purpose of this article is to describe the most popular in internal clinical practice neurologic, endocrine, haematologic, rheumatologic and dermatologic paraneoplastic syndromes associated with cancer.

show abstract

Guillain-Barré syndrome as an atypical manifestation of an esophageal carcinoma

Cited by 9 publications

References 16 publications

Cancer Diagnosis and Prognosis After Guillain–Barré Syndrome: A Population-Based Cohort Study

Cancer Diagnosis and Prognosis After Guillain–Barré Syndrome: A Population-Based Cohort Study

A Case of Paraneoplastic Guillain-Barré Syndrome Associated with Squamous Cell Carcinoma of the Lung

Paraneoplastic syndromes in daily clinical practice

Contact Info

Product

Resources

About